Literature DB >> 16779882

Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma.

C Mariette1, G Piessen, A Lamblin, X Mirabel, A Adenis, J P Triboulet.   

Abstract

BACKGROUND: The aim of this study was to determine the effect of neoadjuvant radiochemotherapy (RCT) on postoperative complications and survival after surgery for locally advanced oesophageal squamous cell carcinoma.
METHODS: Postoperative course and survival were compared in 144 patients who had neoadjuvant RCT and 80 control patients who had surgery alone for locally advanced oesophageal squamous cell carcinoma (radiological stage T3, N0 or N1, M0).
RESULTS: The two groups were comparable in terms of American Society of Anesthesiologists grade, age, sex, weight loss, tumour location, presence of lymph node metastasis and surgical approach. Postoperative mortality rates were 6.3 and 9 per cent (P=0.481), with morbidity rates of 40.3 and 41 percent (P=0.887) in the RCT and control group respectively. Complete resection (R0) rates were 74.3 and 48 percent respectively (P<0.001). Significant downstaging was observed in the RCT group (P<0.001), with 16.0 percent of patients having a complete pathological response. Median survival was 29 versus 15 months, and the 5-year survival rate 37 versus 17 percent (P=0.002) in RCT and control groups respectively.
CONCLUSION: Neoadjuvant RCT significantly enhanced R0 resection and survival rates in patients with stage T3 oesophageal squamous cell carcinoma, with no increase in postoperative mortality and morbidity rates. Copyright (c) 2006 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779882     DOI: 10.1002/bjs.5358

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Risk prediction scores for postoperative mortality after esophagectomy: validation of different models.

Authors:  U Zingg; C Langton; B Addison; B P L Wijnhoven; J Forberger; S K Thompson; A J Esterman; D I Watson
Journal:  J Gastrointest Surg       Date:  2008-12-03       Impact factor: 3.452

2.  Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?

Authors:  Carlo Castoro; Marco Scarpa; Matteo Cagol; Rita Alfieri; Alberto Ruol; Francesco Cavallin; Silvia Michieletto; Giampietro Zanchettin; Vanna Chiarion-Sileni; Luigi Corti; Ermanno Ancona
Journal:  J Gastrointest Surg       Date:  2013-08       Impact factor: 3.452

Review 3.  Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma.

Authors:  Jin Lv; Xiu-Feng Cao; Bin Zhu; Lv Ji; Lei Tao; Dong-Dong Wang
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

4.  Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution.

Authors:  Khashayar Fakhrian; Arif Deniz Ordu; Florian Lordick; Jörg Theisen; Bernhard Haller; Tomislav Omrčen; Michael Molls; Carsten Nieder; Hans Geinitz
Journal:  Strahlenther Onkol       Date:  2014-11       Impact factor: 3.621

5.  Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey.

Authors:  Vahide I Ugur; Sakire P Kara; Bulent Kucukplakci; Taciser Demirkasimoglu; Cem Misirlioglu; Aytul Ozgen; Yesim Elgin; Ergun Sanri; Kadri Altundag; Nadi Ozdamar
Journal:  Med Oncol       Date:  2007-07-20       Impact factor: 3.064

6.  PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.

Authors:  Matteo Fassan; Francesco Cavallin; Vincenza Guzzardo; Andromachi Kotsafti; Melania Scarpa; Matteo Cagol; Vanna Chiarion-Sileni; Luca Maria Saadeh; Rita Alfieri; Ignazio Castagliuolo; Massimo Rugge; Carlo Castoro; Marco Scarpa
Journal:  Cancer Med       Date:  2019-08-20       Impact factor: 4.452

7.  Is there a place for esogastric cancer surgery in cirrhotic patients?

Authors:  Christophe Mariette
Journal:  Ann Surg Oncol       Date:  2008-01-03       Impact factor: 5.344

8.  Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response.

Authors:  Andromachi Kotsafti; Melania Scarpa; Francesco Cavallin; Matteo Fassan; Roberta Salmaso; Andrea Porzionato; Luca Saadeh; Matteo Cagol; Rita Alfieri; Carlo Castoro; Massimo Rugge; Ignazio Castagliuolo; Marco Scarpa
Journal:  Oncoimmunology       Date:  2020-08-12       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.